Published in J Clin Oncol on May 03, 2010
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? J Urol (2015) 2.04
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int (2013) 1.55
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis (2012) 1.42
Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol (2014) 1.42
Modeling grade progression in an active surveillance study. Stat Med (2013) 1.41
Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can Urol Assoc J (2015) 1.38
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging (2013) 1.33
The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol (2013) 1.22
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer (2014) 1.04
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. BJU Int (2013) 0.98
Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer. J Natl Compr Canc Netw (2013) 0.93
Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol (2014) 0.92
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol (2012) 0.89
The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol (2014) 0.89
Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. Adv Urol (2012) 0.87
Prostate cancer: a review of active surveillance. Res Rep Urol (2014) 0.86
Focal cryosurgical ablation of the prostate: a single institute's perspective. BMC Urol (2013) 0.85
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol (2013) 0.85
Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis (2015) 0.85
Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian J Androl (2011) 0.84
Active surveillance for early-stage prostate cancer: defining the triggers for intervention. J Clin Oncol (2010) 0.83
Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr (2012) 0.83
Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men. Urology (2013) 0.82
Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models. J Urol (2013) 0.82
Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes. Asian J Androl (2012) 0.82
Prostate cancer: why is PSA velocity such a sticky concept? Nat Rev Urol (2013) 0.82
Current status of active surveillance in prostate cancer. Investig Clin Urol (2016) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Active surveillance for low-risk prostate cancer. F1000 Med Rep (2012) 0.80
Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance. BJU Int (2015) 0.79
The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges. Prostate Cancer (2012) 0.79
Our results of active surveillance for localized prostate cancer patients. Turk J Urol (2013) 0.78
Active surveillance in men with low-risk prostate cancer: current and future challenges. Am J Clin Exp Urol (2013) 0.78
Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer. Prostate Int (2015) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol (2015) 0.77
Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol (2013) 0.76
Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian J Androl (2012) 0.76
Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl (2015) 0.75
Urological oncology: prostate cancer. J Urol (2010) 0.75
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75
Words of wisdom. Re: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. Eur Urol (2010) 0.75
Prostate cancer: treatment triggers for patients on active surveillance. Nat Rev Urol (2011) 0.75
The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from Turkey. Turk J Urol (2016) 0.75
The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology (2017) 0.75
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer. Urol Case Rep (2016) 0.75
Image-based monitoring of targeted biopsy-proven prostate cancer on active surveillance: 11-year experience. World J Urol (2015) 0.75
The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer. Abdom Radiol (2017) 0.75
A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol (2016) 0.75
Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol (2014) 0.75
Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer. Int J Clin Oncol (2013) 0.75
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Eur Urol (2017) 0.75
[The importance of pathology in the German prostate cancer study PREFERE]. Pathologe (2013) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Complications after prostate biopsy: data from SEER-Medicare. J Urol (2011) 5.40
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol (2012) 4.11
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38